Phase 2 Carb Blocker Clinical Studies


The studies were conducted by the staff of Department of Chemistry of Scranton University.

Clinical Study 1.      

In vivo success of a starch absorption blocker in a double-blind placebo-controlled study with normal subjects.
Analysis data were gained during 2 stages of research: on September 6, 2001 and November, 20, 2001 with the total 20 subjects, nine of which were excluded: those who did not supply all blood samples or had a negative region for the plasma glucose-time curve and were as a result poor absorbers.
Among the subjects there were 8 female and 3 male, at the age from 21 to 57. The Phase 2® group had considerably lower plasma glucose at 60 minutes and nearly considerably lower glucose at 45 minutes. The curve area that characterizes glucose absorption and metabolism was 66% slower due to Phase 2® that has shown effectiveness in both sedentary and physically active participants.

 Clinical Study 2.     

 In vivo success of a starch absorption blocker in a double-blind placebo-controlled study with normal college-age subjects.
One of the methods to reduce hyperglycemia in normal and especially in diabetic subjects is inhibition of carbohydrate metabolism.  The decline in calorie intake after eating carbohydrates for obesity and weight loss could be another possible advantage.
In the result of this study the control bread has shown a glucose augment in the normal subjects that achieved a wide peak after 45 minutes. For the Phase 2® group the glucose peak happened at 30 minutes. The dose of Phase 2® created a slighter enlargement than the control from 15 to 80 minutes, with roughly considerable difference (p < 0.1) at 45 and 60 minutes. The glucose was emitted from plasma about 30 minutes earlier due to Phase 2 in comparison with the control group. The curve area that characterizes glucose absorption and metabolism was 85% lower with the Phase 2®, p < 0.05. Hence only 15% of the glucose penetrated into the body in the presence of Phase 2®. So there is obvious success of Phase 2®in diminishing the glucose absorption from complex carbohydrates.

Clinical Study 3.   

Phase 2® ™ Demonstrates Efficacy When Taken With a Mixed Full Meal

In this study seven participants ate Hungry-Man Frozen Country Fried Beef Steak with 240ml of water that included 630 calories, 64 grams of carbohydrates, 29 grams of fat and 29 grams of protein in the form of breaded beef patties, green beans, mashed potatoes with gravy, mushrooms, and cherry-apple crumb cake. The Phase 2® group received 0.75 grams of Phase 2® mixed in with the mashed potatoes , while the control group had only the meal.
The results were the following: Phase 2® decreased starch amalgamation by 28% when 0.75 grams of the substance was mixed with a full meal and provided to partakers in a random, blinded fashion. This study shows that half the amount of Phase 2® can be efficient in a full meal enclosing carbohydrates, proteins and fat.

Clinical Study 4.      

Starch Neutralizer Promotes Weight Loss, Lowers Triglyceride Levels

Participants who consumed starch neutralizer from the white kidney bean, lost almost a half pound a week (usually better than 200% more than those on placebo) and 1.5 inches around their waists (43% more than those on placebo).
There was also noticed a striking, 26-point fall in triglyceride levels, for participants consuming starch neutralizer  (compared to 8 point drop among control group) that can be a significant addition in upholding a good cardiac profile.
There was also a 13% increase in energy reported by participants on the starch neutralizer, while the absence of such enhancement in the control group.

Clinical Study 5.      

Investigation of the efficacy of Phase 2®, a double-blind placebo controlled crossover study with informed consent

The participants were 5 males and 5 females aged from 21 to 57, all employed at a commercial clinical laboratory.
The results were the following: the extremely small amount of the glucose was absorbed when co-ingested with Phase 2® and the glucose was emitted quickly with no side effects.

Clinical Study 6.      

Summary of clinical study evaluating effectiveness of Phase 2®.

Dr. R. Ballerini conducted his research in Milano, Italy with 60 human healthy volunteers, males and females, aged 20-45 years, with 5 - 15 kg overweight for at least 6 months.  Volunteers were asked to take a pill before a meal full of carbohydrates. All volunteers underwent the weight registration after 10, 20 and 30 days. For the purpose of the study only 60 participants whose weight remained stable during that period were recruited, and then divided in two homogenous groups (sex, age, and weight) and took 1 pill a day. They preserved their regular habits (sport, or any other habits that could affect the study) and pursued the Dietician's nutritional advises.
Phase 2® group showed a good success in lessening of calories intake form complex carbohydrates, easier and balanced weight loss, adipose membrane thickness decrease and a lessening of waistline, hips comparing to placebo group who did not demonstrated any noteworthy change in the considered parameters.
The study revealed the valid capacity of the Phase 2® to resolve weight loss problem by fat mass reduction through lessened absorption of complex carbohydrates.

Clinical Study 7.      

Chronic Toxicity Study Confirms Safety of Phase 2® Ingredient

Phase 2® did not demonstrated any indications of continual toxicity at doses up to 1.0 gm/kg body weight for up to 90 days. Phase 2®considerably lessened food consumption in the Phase 2®groups compared to control. No liver function change was noticed in liver function tests such as GOT, GPT, ALP, Bilirubin, total protein and Albumin/Globulin ratio. No change in the renal function, haematological parameters such as total WBC, differential count and platelets, histopathology of liver and kidney was produced by Phase 2®.
There wasn’t noticed any considerable change in necroscopy of the animals and organ weight of the animals such as liver, kidney, and in the lipid profile of animals treated with Phase 2®.
An LD 50 study for acute toxicity verified that Phase 2® was safe and non-toxic.